Description {#s1}
===========

A 58-year-old woman with no history of smoking was admitted to our hospital with exacerbation of cough. CT of the chest revealed a left upper lobe lung tumour. Bronchoscopic biopsy of the tumour revealed stage IV poorly differentiated adenocarcinoma ([figure 1](#BCR2016216232F1){ref-type="fig"}) with epidermal growth factor receptor (EGFR) gene mutation (L858R point mutation). After cytotoxic chemotherapy (cisplatin and pemetrexed) as first-line therapy, disease progression was identified. For the next 3 years, she was treated with erlotinib, an EGFR tyrosine kinase inhibitor (TKI). Regimens were changed several times (cisplatin, gemcitabine, docetaxel and afatinib) due to disease progression or adverse effects. After 2 months with afatinib, disease progression was again noted. We once again performed bronchoscopic biopsy of the primary tumour, and small cell lung cancer (SCLC) was confirmed from histopathological examination ([figures 2](#BCR2016216232F2){ref-type="fig"}[](#BCR2016216232F3){ref-type="fig"}--[4](#BCR2016216232F4){ref-type="fig"}). Levels of tumour markers such as progastrin-releasing peptide and non-specific elastase were elevated. Moreover, a second examination again detected the EGFR gene mutation (L858R point mutation without T790M point mutation). Amrubicin was administered, resulting in radiologically stable disease. Most cases of acquired resistance to EGFR-TKI arise from the emergence of T790M mutation, and morphological transformation to SCLC is rare.[@R1] After the failure of EGFR-TKI, rebiopsy of the tumour is warranted to determine the next treatment strategy.
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###### Learning points

-   After the failure of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), rebiopsy of the tumour should be performed to determine the next treatment strategy.

-   But it is unclear when to perform rebiopsy after EGFR-TKI failure.
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